OOIR: Observatory of International Research

Papers

(The H4-Index of Journal for Immunotherapy of Cancer is 68. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
T-cell tolerant fraction as a predictor of immune-related adverse events	241
Differential phagocytosis induces diverse macrophage activation states in malignant gliomas	213
Targeting of GSDMD sensitizes HCC to anti-PD-1 by activating cGAS pathway and downregulating PD-L1 expression	204
Lactylation-driven TNFR2 expression in regulatory T cells promotes the progression of malignant pleural effusion	179
Visceral adiposity and systemic inflammation in the obesity paradox in patients with unresectable or metastatic melanoma undergoing immune checkpoint inhibitor therapy: a retrospective cohort study	155
Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors	154
Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study	151
Tumor-associated macrophage-specific CD155 contributes to M2-phenotype transition, immunosuppression, and tumor progression in colorectal cancer	150
Serum albumin: a pharmacokinetic marker for optimizing treatment outcome of immune checkpoint blockade	147
New insights into the role of IFN-α/β and TLR7/8/9 in cancer immunotherapy and systemic autoimmunity	140
Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047	133
MAIT cells promote cancer progression and regulatory T cell accumulation in bladder tumor microenvironment	133
Novel circulating microRNA signature for early detection and prognostication of checkpoint inhibitor-related pneumonitis	127
Immune-related adverse events occurring rapidly after a single dose of immune checkpoint blockade	125
Biomarkers for response to TIL therapy: a comprehensive review	118
Localization and density of tertiary lymphoid structures associate with molecular subtype and clinical outcome in colorectal cancer liver metastases	116
Novel PAP-targeted CAR-T therapy enhances antitumor efficacy through CoupledCAR approach	116
Constructing a pancancer ubiquitination regulatory network to determine tumor characteristics, immunotherapy response, and prognosis	113
Immunotherapy reverses glioma-driven dysfunction of immune system homeostasis	111
Evaluation of immune checkpoint inhibitor efficacy for solid tumors with CD274 (PD-L1 gene) amplification identified by comprehensive genomic profiling: retrospective study based on a nationwid	109
Inhibition of PNCK inflames tumor microenvironment and sensitizes head and neck squamous cell carcinoma to immune checkpoint inhibitors	106
Correction: Dexmedetomidine induces immunogenic cancer cell death and sensitizes tumors to PD-1 blockade	105
B7-H3 CAR-T cell therapy combined with irradiation is effective in targeting bulk and radiation-resistant chordoma cancer cells	103
Intratumoral microbiota predicts the response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer	101
Author response to comment on “Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer	101

Response to "NLRC5 germline variants and their potential role in eliciting an immune response in patients with cancer treated with immune checkpoint inhibitors" by Xiang-Yu Meng	100
Serum analytes as predictors of disease recurrence and the duration of invasive disease-free survival in patients with triple negative breast cancer enrolled in the OXEL trial treated with immunothera	99
Commentary on oncolytic viruses: past, present, and future	96
Correction: Ultrasound combined with nanobubbles promotes systemic anticancer immunity and augments anti-PD1 efficacy	96
Correction: Treg-selective IL-2 starvation synergizes with CD40 activation to sustain durable responses in lymphoma models	95
Checkpoint inhibitor-expressing lentiviral vaccine suppresses tumor growth in preclinical cancer models	95
Zelig Eshhar (1941–2025): a tribute for a life for immunotherapy	93
Correction: Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer	91
Is immunotherapy safe and effective in patients with VEXAS syndrome?	91
Cbl-b inhibitor NX-1607 activates MAPK/ERK signaling pathway and enhances T-cell activation	89
Correction: PP4 inhibition sensitizes ovarian cancer to NK cell-mediated cytotoxicity via STAT1 activation and inflammatory signaling	86
Pancreatic cancer cell-intrinsic transglutaminase-2 promotes T cell suppression through microtubule-dependent secretion of immunosuppressive cytokines	86
Correction: influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors	85
Macrophage-inherited exosome excise tumor immunosuppression to expedite immune-activated ferroptosis	84
Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study	84
Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival	84
Patient-reported outcomes in adoptive cell-therapy trials: mind the gap	83
TIPE2 deletion improves the therapeutic potential of adoptively transferred NK cells	83
GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma	82
Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma	81
Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells	80
Genomic and transcriptomic characterization of heterogeneous immune subgroups of microsatellite instability-high colorectal cancers	80
Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders	80
Hybrid epithelial-mesenchymal status of lung cancer dictates metastatic success through differential interaction with NK cells	79
iRECIST and atypical patterns of response to immuno-oncology drugs	79
Neoantigen architectures define immunogenicity and drive immune evasion of tumors with heterogenous neoantigen expression	79
HDL-cholesterol confers sensitivity of immunotherapy in nasopharyngeal carcinoma via remodeling tumor-associated macrophages towards the M1 phenotype	76
EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses	75
Delivery of CD47 blocker SIRPα-Fc by CAR-T cells enhances antitumor efficacy	74
Tumor-secreted AGR2 induces dendritic cell dysfunction and impairs immunotherapy efficacy in LKB1-deficient cancer	72
Single-cell analysis reveals clonally expanded tumor-associated CD57⁺ CD8 T cells are enriched in the periphery of patients with metastatic urothelial cancer responding to PD-L1 blockade	72
Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy	72
Oncolytic adenovirus serotype 35 mediated tumor growth suppression via efficient activation of antitumor immunity	72
Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision	72
Addendum 1: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0	71
Immune checkpoint blocking impact and nomogram prediction of COVID-19 inactivated vaccine seroconversion in patients with cancer: a propensity-score matched analysis	71
Modulating lipid metabolism improves tumor immunotherapy	70
Comprehensive immunophenotyping of gastric adenocarcinoma identifies an inflamed class of tumors amenable to immunotherapies	70
Efficient CAR T cell targeting of the CA125 extracellular repeat domain of MUC16	70
Vaccination generates functional progenitor tumor-specific CD8 T cells and long-term tumor control	68
Paclitaxel, interferons and functional reprogramming of tumor-associated macrophages in optimized chemo-immunotherapy	68
PD-1 blockade employed at the time CD8+ T cells are activated enhances their antitumor efficacy	68
Targeting immunosuppressive macrophages by CSRP2-regulated CCL28 signaling sensitizes hepatocellular carcinoma to lenvatinib	68